CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure

Anti-Amyloid Debate Continues With Mixed Readouts

 
• By Mandy Jackson
  
Brain image on blue background
Lecanemab's efficacy may hinge on the type of amyloid it clears from the brain • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D